Bio-Techne Corp (TECH)vsVertex Pharmaceuticals Inc (VRTX)
TECH
Bio-Techne Corp
$52.69
+0.50%
HEALTHCARE · Cap: $8.20B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 887% more annual revenue ($12.00B vs $1.22B). VRTX leads profitability with a 32.9% profit margin vs 6.7%. TECH appears more attractively valued with a PEG of 0.66. VRTX earns a higher WallStSmart Score of 66/100 (B-).
TECH
Hold48
out of 100
Grade: D+
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-460.5%
Fair Value
$11.32
Current Price
$52.69
$41.37 premium
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
ROE of 4.0% — below average capital efficiency
6.7% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : TECH
The strongest argument for TECH centers on Altman Z-Score, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : TECH
The primary concerns for TECH are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 98.9x leaves little room for execution misses.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
TECH profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
TECH carries more volatility with a beta of 1.48 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 48/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bio-Techne Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?